Ticrynafen, a uricosuric antihypertensive diuretic

Area of Science:

• Pharmacology
• Nephrology
• Cardiology

Background:

• Ticrynafen is a diuretic-uricosuric agent with antihypertensive properties.
• Understanding its comparative efficacy and uricosuric effects is crucial for clinical application.

Purpose of the Study:

• To compare the natriuretic and uricosuric effects of ticrynafen with other diuretics.
• To evaluate the additive effects of ticrynafen in combination with other diuretics.

Main Methods:

• Single-dose comparison of ticrynafen (250 mg and 500 mg) with chlorthalidone, ethacrynic acid, furosemide, and hydrochlorothiazide.
• Assessment of natriuretic activity over an 8-hour period.
• Evaluation of uricosuric effects and effects in combination therapies.

Main Results:

• A 250 mg dose of ticrynafen showed natriuretic activity similar to 25 mg chlorthalidone and 50 mg ethacrynic acid.
• A 500 mg dose was comparable to 50 mg chlorthalidone and 50 mg hydrochlorothiazide in natriuretic effect.
• Ticrynafen exhibited a uricosuric effect, maintained in combination with furosemide and hydrochlorothiazide, which are typically antiuricosuric.

Conclusions:

• Ticrynafen demonstrates dose-dependent natriuretic effects comparable to established diuretics.
• Its inherent uricosuric property may be advantageous in patients prone to hyperuricemia.
• Ticrynafen offers a potential therapeutic option for managing hypertension and fluid retention while mitigating hyperuricemia risk.